Naturalendo Tech Co., Ltd. Novel Proprietary Standardized Healthcare Ingredient.

Naturalendo Tech Co., Ltd.

Success Story of EstroG-100

Novel Proprietary Standardized Healthcare Ingredient

2

Established in May 24, 2001

Headquartered in Pangyo (10 minutes from Gangnam (Seoul)), Korea

Initial Public Offering: Oct 31st, 2013 in KOSDAQ

Business Lines:

Proprietary Herbal Remedy (EstroG-100)

IGF-1 Secretagogue (YGF-251)

Hormone Disruptor Inhibitor

Immune Enhancer

Skin Care Formula, etc.

2014 Sales Revenue: $ 124 mil. in 2014

In-house Manufacturing Facility

Fastest growing bio venture & largest biotech in terms of the sales of in-house developed health functional food ingredient in Korea

Company Profile - Facts & Figures

3

Characteristics of Healthcare Industry

Healthcare Industry

Device & Equipment

U – Healthcare

Pharmaceutical

Nutraceutical

Cosmeceutical

OthersInsurance

Health Machine

Hospital & Clinics

Novel Ingredient

Our Products

hGH Secretagogue

EstroG-100

Derma A2

TDDS

Difficult to enter into a market due to long-term investment in R&D and a massive capital investment High value-added industry Service to the Public Health Insensitive to Economy Fluctuation

Summary of Healthcare Industry & Our Product Line-up

4

Function of Estrogen

Growth and development of uterus and mammary gland Expression of secondary sex characteristics Control of menstrual cycles and supporting pregnancy

Bone metabolism and increase of BMD Cardiovascular health and lipid metabolism Anti-dementia, trophic factor for neuron

Colon cancer prevention Teeth health Prevention of macular degeneration

Fat distribution to subcutaneous fat tissue Collagen production and maintaining human skin

5

Menopause Classification Premature Menopause

About 8% Women (US) stop having period before age 40 Same symptoms as Menopause

Peri-menopause

Average women go through this phase age 45~49 Wildly fluctuating Estrogen Level Same symptoms as Menopause

Menopause

Estradiol level<50 pg/mL; FSH>50 mIU/mL; no period for >1 yr* Average age for onset of menopause is 52 in US Symptoms last 2~19 years, many more than 5 years

Surgical Menopause

After Hysterectomy/Bilateral surgery

* Definition: Dr. Joel Harglove, MD, Chairman, Vanderbilt Menopause Center, Nashville, TN

6

After Menopause, Women Suffer…Women spend almost half of their lives in pre-, peri- and post-menopause. Physiological /Psychological Changes During Menopause

Hot flashes, Night sweats Vaginal dryness & thinning of vaginal wall Inelastic skin and dry eye, insomnia, nervousness, depression,

paresthesia(numbness), vertigo(dizziness), fatigue, rheumatic pain(joint), pounding of heart, headaches

Long Term Post-Menopausal Health Risks

Cardiovascular Diseases (CVD’s) : 2 times higher risk of CVD’s after menopause Osteoporosis

ESTROG-100

8

Executive SummarySolution for Women’s Quality of LifeEstroG-100 is dominating the Korean market by occupying over 90% share of total menopause market, including HRT and herbal remedies.

Features

Patents, Licenses, and approvals

•17 registered and pending patents worldwide

•Health Canada NPN License

•NDI Notification Accepted by US FDA

•HFFI by MFDS (Korea FDA)

•Expected to obtain Novel Food Approval from EU Commission 1Q 2015

Benefits

•Clinically proven efficacy and safety

•Significant improvement of 10 menopausal symptoms out of 12 in total

•QOL improvement

•FBMD significantly improved

•No side effects compared to other alternatives including HRT, Black Cohosh and Isoflavone.

Market Status

•Successful sales in Korea, US, Canada and Southeast Asian countries.

•Ranked No.1 over more than 45 products of HRT & Black cohosh since 2011 in Korea

•Supplying to Korean major companies & its sales hit 340milliion USD in retail price in 2014

9

Competency

R&D & Commercial-ization of

Novel Healthcare In-gredients

R&D Center• Diverse Pipeline & Differentiated

R&D Patents

Production & Purchasing• In-house Manufacturing Site• Contract Farming

Marketing & Sales• Differentiated Marketing & Ma-

jor Company Loyalty

ESTROG-100A. POSITIONING IN THE INDUSTRY

11

New History on Healthcare IngredientsSales of Major Herbal Medicines

Stillen: the Korean Blockbuster Herbal Medicine of Dong-A Pharm sold in US$85 mil.

Joins: the Korean Major Herbal Medicine of SK Chemical in US$35 mil. (Ministry of Health & Welfare, 2012)

Factive: the 1st Korean Drug approved by U.S. FDA sold in US$17 mil in 2011 but decreased to US$9 mil. in 2012 (Asia Economics, 2013)2005 2007 2009 2012

0

10

20

30

40

50

60

70

80

90

Joins Tab.

Stillen Tab.

Sales of EstroG-100 in Retail Price

2010 2011 2012 2013 20140

50

100

150

200

250

300

350

400 (million USD) EstroG-100 has been supplied for Korean majors and its sales hit in Retail Price:

2010 USD 9 mil. 2011 USD 55 mil. 2012 USD 100 mil. 2013 USD 270 mil. 2014 USD 340 mil.

(million USD)

12

Dominance in Korean Menopause Market

2010 2011 2012 201324.4%

51.1% 66.0%

85.0%

63.5%

41.7%

29.4%

13.2%

12.1%

7.2%

4.6%

1.7% Other Phytoestrogen HRT EstroG

Market Share in Korea Menopause Market

Source : Korea Pharmaceutical Manufacturers Association, Korea Export Association

Began sales from Aug. 2010

* Total sales have been converted to consumer prices since we have been supplying EstroG in the type of ingredient, semi-finished products, finished products, and our own brands.

•Established $340m market

2014

•Established $270m market

2013

•Established U$100m market Dominating over Other Ingredients

2012

•No.1 Ingredient in Korea

2011

(W100mn)

13

Global Estrogen Market Share

Line-up of Major Global Partners Global Sales to Increase

Replacing Global Pharma + Supplement Market

2.1% 26.8%

15.0%9.5%

45.9%

Naturalendo

Pfizer

Novo Nordisk

Warner Chilcott

Other

9.0%

25.8%

14.2%8.9%

42.2% 2013

2012

11.1%

25.1%

13.9%

8.7%

41.2% 2014

* Global sales of HRT products and Naturalendo’s sales converted to consumer price.

14

Penetrating Global Market

ESTROG-100B. COMPETITORS IN THE MARKET

16

Other Estrogen Alternative - (1) HRTWomen’s Health Initiative Study (WHI) National Institute of Health (NIH) sponsored 8.5-year study with 16,000 subjects to es-

timate the benefits and risks of HRT The Study was terminated early at 5 years with increased risks of breast cancer (26%),

CVD (22%), stroke (41%), coronary heart disease (29%), blood clots (100%), Alzheimer's (100%)

US FDA required “Black Box Warning” Prescribed ONLY for <4 weeks

JAMA July 2002

17

Negative Results of WHI’s Clinical Studies on HRT

JAMA 2004; 291; 1770

Non-hormones release

Side effects of hormones reported

Low-dose hormones release

Ref: GBI Research (2009)

In U.S., HRT prescription significantly dropped since 2002

“Soaring Needs for Safe and Natural Alternative, EstroG-100”

Other Estrogen Alternative - (1) HRT

18

Other Estrogen Alternative - (2) PomegranatePomegranate, just a fruit“Any estrogen is not included under error range in this prove. In addition, any estrogen is proven not to be detected in 7 different pomegranate fruits. Coumestrol the phytoestrogen is not detected in the supplements either not as known to public to be included in the seeds.”

ザクロを使った健康志向食品 - エストロゲンは本当に含まれているの？(Supplement using pomegranate – Estrogen included?)

国民生活センター, ［ 2000 年 4 月 6 日 : 公表］ http://www.kokusen.go.jp/news/data/n-20000406_2.php3

● 結果・現状　今回調べた範囲ではエストロゲンは検出限界以下で検出されなかった。また、延べ 7 個のザクロ果実を調べた結果でもエストロゲンが含有されていることの確認はできなかった。またザクロの種子に含まれていた植物ホルモンのクメステロールも健康志向食品からは検出されなかった。

独立行政法人国民生活センターの概要

( 情報公開法第２２条に規定する情報の提供）国民生活の安定及び向上に寄与するため、総合的見地から、国民生活に関する情報の提供及び調査研究を行うこと。 http://www.kokusen.go.jp/

http://www.kokusen.go.jp/hello/index.html

http://www.kokusen.go.jp/news/data/n-20000406_2.php3

http://www.kokusen.go.jp/news/data/n-20000406_2.php3

http://www.kokusen.go.jp/

19

Other Estrogen Alternative - (3) Black CohoshVulnerability of Black CohoshThe U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised that a warning label would be placed on the all black cohosh products due to 21 reported cases of liver problems associated with black cohosh use (MHRA, 2006)

At the end of one year, there was no signif-icant difference seen between the number of daily hot flashes and/or night sweats in any of the herbal groups compared to the placebo group, with an average of 0.6 less vasomotor symptoms per day in the herbal groups. There was a significant difference-4.06 fewer symp-toms per day-in the hormone therapy group compared to the placebo groups

01/15/2007 07/30/2007

The committee reviewed case reports suggesting a potential link between inges-tion of the extracts and liver damage

20

Other Estrogen Alternative - (3) Black Cohosh

As of Oct 2012, due to 36 out of 53 case reports related to black cohosh involved liver problem, MHRA has warned manufacturers of black cohosh products that the herbal sup-plements must contain warnings about potential liver problems (MHRA 2012).

http://www.nutraingredients.com/Regulation/UK-tells-black-cohosh-makers-to-add-warnings-and-backs-THMPD

http://www.nutraingredients.com/Regulation/UK-tells-black-cohosh-makers-to-add-warnings-and-backs-THMPD

21

Other Estrogen Alternative - (4) Isoflavone

Genistein (a major isoflavone aglycone) may cause Cancers (NIH & FDA – National Toxicology Program, Genistein Final , Jan, 2008)

Exposure to Genistein for 2 years caused mammary gland /pituitary gland ade-noma in female rats.

Exposure to Genistein for shorter dura-tion following birth was also possibly as-sociated with increased rates of pitu-itary gland and mammary gland tumors.

Cancer Causing Risks

Isoflavone Could be Toxic because its high level of hormone-like action.

It could be Hormone Dependent Cancer Causing Material due to its high binding affinity to Estrogen Receptor α, and β

Relative Binding Affinity

α β

Estradiol 100 100

Coumestrol1) 94 185

Genistein2) 4 87

1) Kuiper et al, Vol 139, No. 3, Endo 1997 2) Vol 138, No. 10, Endo 1998,

22

EstroG-100’s Superiority over Others

EstroG-100 Pomegranate Soy Isoflavone Black Cohosh HRT

Improved Symptoms 10 1

(Hot Flush)X Partially Some Improved

Improvement of vaginal dryness O X O

Bone metabolism index O X O X O

Bone density O (FBMD) X O X O (Spine)Triglycerides O X

Side Effects X X

Cancer Related

(limitation on dosage)

Liver Damage Fatal Side Effects

Increase of Body Weight & BMI X - X O

E2, FSH Changes X X O

Development In the 2000s In 1998 In the 1990s In the 1940s

Related Patents 17 registered and pending patents X

ESTROGC. SCIENCE OF ESTROG-100

24

EstroG-100 (1)Science of New Herbal Ingredient

Proven Safety

About 400 years of documented use in Korea as folk medicine Registered as safe food ingredient in Korea Food Code Cynanchum wilfordii & Phlomis umbrosa are reported to be liver-protective plants to WHO No increase of uterus weight in ovariectomized rat tests Inhibition of proliferation of human breast cancer cell (MCF-7) No binding Affinity to both Estrogen Receptor α and β, Safe: Acute & Multi-dose toxicity tests , Genetic toxicity tests

Proven Efficacy in vitro, in vivo, and in 3 human group (Asian and non-Asian) clinical studies

Herbal extracts screened out of 71

herbal extracts via non-reproductive tract tar-

get tissue response (E-screen test)

3 herbal extracts were chosen:

Cynanchum wilfordii, Phlomis umbrosa, and

Angelica gigas nakai

25

EstroG-100 (2) Clinically proven efficacy : 62% significant improvement of QOL 10 out of 12 climacteric symptoms significantly improved compared to

Placebo

Improve Menopausal Symp-

toms

Hot flash/ Night Sweats

Paresthesia

Insomnia

Nervousness

Melancholia

Vertigo

Fatigue

Rheumatic pain

Formication

Vaginal Dryness

62%Improvement of symptoms

26

Clinical Study IProtocol

EfficacyClimacteric Symptoms 5 times better improvement than placebo with significance

Clinical Study ITest Method Randomized Double-blind Placebo-controlled study

Study Location School of Medicine, Sungkyunkwan Univ. Samsung Cheil Hospital

Dosing period 12 months (May 2003-April 2004)

Evaluation Style Long Term Safety Evaluation

Patients (n=47) 23 subjects in placebo group & 24 active group

Inclusion Criteria Age of 46 ~ 66 & Diagnosis of menopausal syndromes (average age=54)

Climacteric Symptoms 5 times better im-provement than placebo with significance

After 3 monthsOR=5.04 (95% C.I.=1.4-18.1)Fisher’s Exact Test

Femoral Bone Mineral Density 0.746±0.10 → 0.763±0.13 (P<0.05)

Serum hGH Level 0.25±0.21 → 0.92±0.97 (ng/mL) (P<0.05)

Serum Osteocalcin Level 6.02±2.74 → 5.66±3.01 (ng/mL) (P<0.05)

Serum Triglyceride Level 119.1±54.72 → 92.16±49.94 (mg/dL) (P=0.066)

Serum Alkaline Phosphatase Level 73.35±21.02 → 60.42±14.87 (IU/L) (P=0.08)

27

Randomized, Double-blind, Placebo-controlled Study (CA, USA)

Dosing period 3 months

Patients (n=61) 32 subjects in placebo group & 29 active group

Inclusion Criteria Age of 42 ~ 70, Diagnosis of menopausal syndromes(average age = 53)

Ad for Volunteers for US Clinical Study

Clinical Study II - Protocol(Non-Asian)

28

Somatic / Physical:• Hot flush/ Night sweat • Paresthesia (numbness on hands/foot) • Vertigo (dizziness)• Fatigue• Muscular skeletal pain

Physiological / Psychological:• Nervousness• Insomnia• Depression• Formication

Vaginal Dryness (Difficulties in Sexual Intercourse)

Efficacy of EstroG-100Kupperman Menopause Index and Vaginal Dryness (Difficulties in Sexual Intercourse) Improved Significantly

EstroG-100 was confirmed to improve both somatic and physiological symptoms with statistic significance.

Clinical Study II – Result (1)

29

SE: Standard Error*: Statistically significant compared between groups; p<0.05 by t–test(ITT)**: Statistically significant compared between groups; p<0.01 by t–test(ITT)††; p<0.01 compared between groups by Wilcoxon rank sum test#; p-<0.05 compared to baseline, ##; p<0.01 compared to baseline by paired t-test

EstroG-100Mean±SE

PlaceboMean±SE

Week0 (Baseline) 1.45±1.02 1.75±1.11

Week6

Change from base-line

0.72±0.88

-0.72±0.84**††##

1.50±1.11

-0.25±0.57#

Week12

Change from base-line

0.59±0.87

-0.86±0.88*##

1.28±1.02

-0.47±0.72##

P=0.0536

Fig. 1. Changes of vaginal dryness and reduced libido during 12 weeks administration of EstroG-100 and placebo.

Vagi

nal d

ryne

ss

scor

es

Vaginal Dryness


Vaginal Dryness Improved Unlike Black cohosh and Isoflavone

30

SE: Standard Error**: Statistically significant compared between groups; p<0.01 by t–test(ITT)††; p<0.01 compared between groups by Wilcoxon rank sum test##; p<0.01 compared to baseline by paired t-test

EstroG-100Mean±SE

PlaceboMean±SE

Week0 (Baseline)

29.45±7.39 29.16±6.55

Week6Change from base-line

13.62±7.61

-15.83±9.10**††##

23.31±8.96

-5.84±6.15##

Week12Change from base-line

11.31±5.78

-18.14±8.46**††##

23.66±7.68

-5.50±5.34##

Fig. 2. Changes of Kupperman Menopause Index(Mean±SE) during 12 weeks administration of EstroG-100 and placebo.

0 6 120

5

10

15

20

25

30

35

EstroG-100

** **

Kupperm

an index

score

s

Time (weeks)

Kupperman Index for Moderate or Severe Menopausal Symptoms Improved

KMI


31

EstroG-100 (n=29) Placebo (n=32)

Week 0 Week 6 Week 12 Week 0 Week 6 Week 12

Vasomotor 2.24±0.69 1.03±0.82**††## 0.79±0.73**††## 2.22±0.66 1.78±0.75## 2.06±0.76

Paresthesia 1.31±0.85 0.59±0.78*†## 0.55±0.74*†## 1.41±0.91 1.13±0.94# 1.09±0.96##

Insomnia 2.28±0.84 1.28±0.96**†## 0.97±0.82**††## 2.03±0.86 1.63±1.01# 1.63±0.87#

Nervousness 1.72±0.88 0.76±0.69**††## 0.66±0.67**††## 1.56±0.84 1.22±0.83 1.34±0.75

Melancholia 1.93±0.88 1.03±0.68**††## 0.83±0.71**††## 1.59±0.95 1.31±0.93 1.31±0.74

Dizziness 0.97±0.82 0.21±0.49**††## 0.21±0.41**††## 0.75±0.72 0.72±0.77 0.59±0.80

Fatigue 2.21±0.77 0.90±0.77**††## 0.72±0.70**††## 2.00±0.88 1.69±0.90# 1.59±0.80#

Arthritic Pain 1.59±1.02 0.79±0.94**†## 0.55±0.78*†## 1.84±0.95 1.63±0.83 1.47±0.88

Headache 1.34±1.04 0.69±0.76## 0.66±0.77## 1.53±0.95 1.13±0.91# 0.84±0.72##

Palpitation (heart poundering) 1.00±0.96 0.48±0.69# 0.55±0.63# 1.31±0.93 0.91±0.82## 0.75±0.84##

Formication 0.83±0.85 0.14±0.44* ## 0.28±0.45## 1.25±1.05 0.88±1.01## 0.72±0.96##

*; p-<0.05 compared between groups, **; p<0.01 compared between groups by t –test †; p-<0.05 compared between groups, ††; p<0.01 compared between groups by Wilcoxon rank sum test, #; p-<0.05 compared to baseline, ##; p<0.01 compared to baseline by paired t-test

Individual Menopausal Symptoms


32

Clinical Study III - Protocol

Clinical Study III

Test MethodMulti Center,Randomized double-blind placebo-controlled study

Study LocationAju University Medical Center Anam Hospital of Korea UniversitySeverance Hospital of Yonsei University

Test period 12 weeks

Dosage 638 mg tablet orally twice a day

Study Participants 96 female participants of age of 40~70 with menopausal symptoms

Inclusion Criteria Age of 40 ~ 70 with menopausal symptoms

33

Clinical Study III - Result

The result almost duplicate the 2nd Clini-cal Study (Non-Asian) by improving as many as 10 different symptoms.

No significant differences or changes ob-served when measured endometrial thickness.

No change in weight, BMI, and the level of estrogen and FSH without any adverse event reported during the study. The en-dometrial thickness was measured to be observed not to change in addition.

Significantly Improved!

34

Efficacy of EstroG-100 (1)EstrogenicityIn e-screen test, the estrogen-specific alkaline phosphatase has significantly in-creased and synergetic effects of EstroG-100 has been confirmed

E-screen test: Screen herbal extracts for Estrogenicity

Synergetic Effects of 3 Constituent herbal extracts confirmed

Lee at al., Lab. Anim. Res. 24(2): 167-172 (2008)

0

0.2

0.4

0.6

0.8

1

1.2

1.4

G1 G2 G3 G4 G5 G6 G7 G8 G9

Group

Ute

rus a

nd

ovary

weig

ht

(g

)

*

*

0

1

2

3

4

5

6

7

G1 G2 G3 G4 G5 G6 G7 G8 G9

Group

Os

teo

ca

lcin

(n

g/m

L)

* *

*

* *

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

G1 G2 G3 G4 G5 G6 G7 G8 G9

Group

FB

MD

* (g

/ ㎠) *

* * *

**

**

Significantly improved in serum osteocalcin and FBMD in OVX rat No change in weight, liver, kidney, and uterus weight in OVX rat

Kim at al., Kor. J Food Sci. Technol. 40(3): 316-320 (2008)

Uterus weight Serum osteocalcin FBMD

35* One month Open Label Clinical Study by HiLiving, the No.1 MLM firm among local capital MLM companies in Korea with 119 participants

75% higher satisfaction rate compared to the existing Isoflavone product 69% picked “Better Efficacy” for the top reason for the higher satisfaction

Efficacy of EstroG-100 (2)

36* One Month Open Label Clinical Study by Pulmuone Health Care with 31 participants

86% decrease in menopausal symptoms compared to 39% of the Isoflavone product Sales volume increased 2.5 times, satisfaction/repurchasing/ recommendation rate

soared

Isflavone EstroG-1000%

20%

40%

60%

80%

100%

Satisfaction Rate


50%

100%

150%

200%

250%

Sales Volume/Month

Isflavone EstroG-1000

1020304050607080

Repeat Order Rate


10%20%30%40%50%60%70%80%

Recommendation Rate


37

Wrinkles, Hot Flashes, and Moisture Significantly Improved

* One month Open Label Clinical Study by LG Household & Health Care for 6 weeks with 30 participants


38


Hot flush and vaginal dryness, 33 % of total improved cases. • Out of 20 participants, 10 partic-

ipants showed the improve-ment of menopausal symptoms within 7 days after taking Es-troG-100. The main improve-ment symptoms were hot flush and vaginal dryness, 33 % of to-tal improved cases.

Symptoms Cases %Hot flush 11 20%

Paresthesia 4 7%Insomnia 3 6%

Nervousness 3 6%Melancholia 3 6%

Vertigo 4 7%Fatigue 5 9%

Rheumatic pain 3 6%Formication 2 4%Headache 2 4%Palpitation 2 4%

Vaginal dryness 7 13%PMS 2 4%

Menstrual pain 2 4%Restarting menstruation 1 2%

Total 54 100%

* Open Label Clinical Study by Kim Jung Moon Aloe for 4 weeks with 20 participants

39

Safety of EstroG-100 (1) Safety in 3 human clinical studies

No serious adverse effects – not even a single case of vaginal bleeding / spotting

No change in uterus weight, body weight and BMI (while bone mineral density increase)

None of serious side effects reported in 3 clinical studies without E2, FSH level change

No change in blood pressure, blood sugar, cholesterol, LDL/HDL No change in endometrial thickness

Other Proven features

All three herbs have been documented for use as herbal remedy for +400 years in Korea

All three herbs are registered in Korea Food Standard Codex as main food material

Cynanchum wilfordii and Phlomis umbrosa are reported to be liver protective herbs by WHO

40

Safety of EstroG-100 (2)MCF-7 proliferation inhibitionInhibitory effect of proliferation of human breast cancer cell line (MCF-7)

Estrogen receptor binding affinity testNo binding affinity to both ERα & ERβ in estrogen receptor binding affinity study

EnBio Estrogen Receptor / Coactivator, Ligand Assay System

41

Safety of EstroG-100 (3)Toxicology Single oral toxicity study

No specific toxic symptoms in relation to test substance were observed Minimal lethal dose (MLD) > 4,000 mg/kg (HED = 648.6mg/kg)

Thirteen-week repeated (91 day) oral dose toxicity study of in Sprague-Daw-ley rats No observed adverse effect level (NOAEL): upward 1,000 mg/kg in the male and female group

Genetic Toxicity Study – proven non-toxicity Ames (Bacterial Reverse Mutation), Micronucleus, Chromosome Aberra-

tion

42

Mechanism of Action (1)There are 4 different traditional methods of screening candidate plants for estrogenecity.

a. E-screen assay to see non-reproductive tract target tissue response for a certain plant extract to induce alkaline phosphotase or ALP √ confirmed

b. Reproductive tract response for a certain plant extract to change uterus weight of ovariectomized rats (now, just for safety) √ confirmed

c. Receptor binding affinity test (now, just for safety) √ confirmed

d. Gene reporter vector assay (now, just for safety)

EstroG-100: In a non-reproductive tract target tissue response for e-screen assay, all of the 3 con-stituent herbal extracts of EstroG-100 found to promote estrogen-specific ALP activity to show estrogenic action while EstroG-100 promoted more than any of the individual herbal extract (Lee et al. Anti-menopausal effect of the newly-developed phytoestrogen, FGF271 (=EstroG-100), in vitro and in vivo. Lab. Anim. Res. 24(2): 167-172(2008).) In the earlier study that has not been published, the 3 constituent herbal extracts of EstroG-100 were se-lected out of 71 different herbal extracts by this e-screen assay.

43

Mechanism of Action (2)Even though the exact mechanism has not been clarified, the following available evi-dences suggest that some phytochemicals in EstroG-100 act as estrogen agonists and/or antagonists without influencing the levels of estradiol (E2) and follicle stimulating hor-mone or FSH: In two researches for the reproductive tract target tissue response, EstroG-100 did not increase the

uterus weight of ovariectomized rats while it increased femoral bone mineral density. (Kim et al. Ko-rean J. Food Sci. Technol., 2008 and Lee et al. Lab. Anim. Res. 2008)

EstroG-100 did not show any affinity to both estrogen receptor alpha and beta in the receptor bind-ing affinity test reported by Chungbuk National Univ. of South Korea

Each herbal extract of EstroG-100 showed inhibitory effect of the proliferation of human breast can-cer (MCF-7) cells

In three randomized double-blind placebo controlled clinical study, EstroG-100 improved menopausal symptoms without any serious side effects with no increase of body weight and BMI and without influencing level of E2 and FSH (Lee et al. Evaluation of effectiveness and safety of natural plants extract (Estromon(=EstroG200)) on perimenopausal women for 1 year. J of Korean Society of Menopause. 11(1): 116-26 (2005)

In other clinical study performed in U.S. that was finished on Feb. 2010, EstroG-100 significantly im-proved menopausal symptoms of non-Asian American women without any side effect (Chang et al. The Effect of Herbal Extract (EstroG-100®) on Pre-, Peri-, and Post-Menopausal Women: A Ran-domized Double-Blind Placebo-Controlled Study. Phytother. Res. 26: 510-516 (2012)).

ESTROG-100D. APPROVALS & LICENSES

45

Approvals & Licenses (NDI)NDI Notification Accepted by US FDA (2010)EstroG-100 is listed as New Dietary Ingredient

※ The Federal Food, Drug, and Cosmetic Act (the act) requires that manufacturers and distributors who wish to market dietary supplements that contain “new dietary ingredients” which has not been distributed in USA market before 1994, notify the Food and Drug Administration about these ingredients. Generally, the notification must include information that is the basis on which manufacturers/ distributors have concluded that a dietary supplement containing a new dietary ingredient will reasonably be expected to be safe under the conditions of use recommended or suggested in the labeling. The NDI notification process is complex. NDI notifications are most often rejected due to insufficient evidence for safety, the absence of required elements, as well as lack of knowledge and experience for such notifications.

46

Approvals & Licenses (NPN)NHPD Product License, Health Canada (2011)According to Health Claim, 10 Symptoms Improved!

http://webprod3.hc-sc.gc.ca/lnhpd-bdpsnh/info.do?lang=eng&licence=80026169

Date of License: July 5, 2011Natural Product Number(NPN): 80026169Helps to relieve the symptoms associated with menopause such as hot flashes, night sweats, paresthesia(numbness on hands/foot), insomnia, nervousness, melancholia(depression), vertigo(dizziness) , fatigue, rheumatic pain and vaginal dryness.

Approved Claims with No Side EffectsAccording to Health Claim, 10 Symptoms Improved!

Risk Information:

None.

47

Approvals & Licenses (HFFI)

Approval No: 2010-20Claim: Help with climacteric women’s health

EstroG-100 is the first approved ingredient in Korea as Health Functional Food Ingredi-ent by KFDA for alleviating menopausal symptoms such as hot flashes, night sweats, paresthesia(numbness on hand/foot), insomnia, nervousness, melancholia(depression), vertigo(dizziness), fatigue, rheumatic pain and vaginal dryness and formication

Health Functional Food Ingredient (HFFI) Approval by MFDS (Korea FDA) (2010)

48

EU Approval Status

2014.06Received Positive Assessment by Irish Authority

2014.09~2014.11EU Member States re-viewed the Irish Au-thority’s opinion

2014.12Final comments submit-ted to EU Member States for assessment on novel food approval for EstroG-100

2016.03Expecting to obtain Novel Food Approval

NOW

49

Initiated branch establish-ment

2013.09

Partner with Registration Agency

2014.01

Applied for trademark for Es-troG

2014.04Technical Review by CFDA

2015.02~

Decision Delivery by Administrative Service Center

2015.12~2016

China Approval Status

NOW

ESTROG-100E. PRODUCTS & PARTNERS

51

Major Products & PartnersSupplying Ingredients for Global Clients in S. Korea, U.S., Canada, Singapore, Malaysia, Thailand

Major Partners (Domestic)

Major Partners (Overseas)

EstroG Finished Goods

EstroG Ingredients

BAEKSUO QUEEN(Lotte & CJ Home

Shopping)

KGC(Hwaaelak Queen)

Major Products

NOWFOODS(Herbal Pause)

Donga BAEKSUO(Donga Pharm)

EstroG ODM

52

　　　　

Multi Symptom Menopause Relief

(Walgreens)

8 Symptom Advanced Menopause Relief

(CVS Pharmacy)Herbal Pause (NOW Foods)

Best EstroG-100 (Doctor's Best)

Advanced Natural Sex for Women 50+ (Life Extension)

　　　　　

Ultra EstroG-100 (Swanson)

Profemin (TheraBotanics LLC)

Intimate Comfort (Healthy Directions )

Zestrogen (Purity Products)

Advanced 8-SymptomMenopause Relief

(Meijer)

　　　　　

Venus and Mars (Dr. John Gray, Inc.)

EstroPrime Plus (Allergy Research Group)

Flashes No More (Nutricology)

n-fuzed Estro-Fem (Harmonic Innerprizes Inc)

HerbaEst Balance (New Spirit Naturals)

Products (US)

ESTROG-100F. IN-HOUSE MANUFACTURING FACILITY

54* In-house Production Capa of 10 ton/month

In-house Manufacturing FacilitySecuring supply of raw ingredients for GMP level manufacturing through contract farming

Completed Construction of GMP Facility (September 2014)Contract Farming for EstroG Raw Material

Expected effect from in-house production

Strict control over quality

Secure sustainable supply of ingredient through increase in Capacity

Profit increase by reducing production cost

Secure raw material supply through contract farming

Stable supply of ingredients through contract farming

Easy to grow & harvested annually in autumn.

High resistance to decay

In-house low temperature warehouse to ensure the best quality of raw materials

300

In-houseCAPA

Total CAPA

Capacity(Ton)

300

160

'13 '14

120

ESTROG-100G. MEDIA COVERAGE

56

Media Coverage (1) EstroG-100® was mentioned on national Canada TV show, Steven and Chris

on January 22nd, 2015.

57

Media Coverage (2)

KBS Science Café – Science of Hormone (April 9th, 2012)

SBS Special : Rediscovery of Korean Herb (Mar. 3rd , 2013)

The largest and state-run Korea Broadcasting System or KBS reported on hormone in their program called Science Café. It dealt the science of hormone and introduced EstroG-100 as a safe new product for menopause.

The most popular privately owned TV channel, SBS Special Documentary featured EstroG-100 for 1 hour: its history, science & technology, testimonials from MDs and end users, and other distinctive aspects.

“Traditional Korean herb extracts pullingGlobal attention and being exported to theWorld.

58

TV Commercial featuring on KBS and MBC SBS News Health Report(July, 2012)

MBC Power Magazine(Oct., 2012)TV Commercial featuring on KBS and MBC

Media Coverage (3)TV Commercials & Others

59

Press Coverage (1)

Life Extension Magazine, May 2012“EstroG-100™, this multi-compound extract supports balanced estrogenic activity, which in turn inhibits the many symptoms of menopause including female sexual dysfunction”

60

Press Coverage (2)

61

Home Shopping & Infomercial

Launched through infomercial in US in June 2014

Launched through 5 Major Home Shopping Channels in Korea

ESTROG-100H. AWARDS

63

Awards (1)

Awarded Presidential Bronze Tower Indus-trial Order Service Merit, in recognition of contribution to the development of industry and the national economy.

2014 Bronze Tower Industrial Order (Presidential Award), Korea Creative Economy Expo

64

Awards (2)

Best Botanical Award at Natural Products Expo West in US (2014)

Awards (3)Korea’s Top 10 Most Innovative Technolo-gies (2013)EstroG-100 was awarded for “Korea’s top 10 inno-vative technologies” in 2013. This award is given only for the product that is the most promising and potential of the year in all industry.

For ‘EstroG-100’ by Ministry of Trade, Industry and Energy

Korean World-class Product Award (2011)

World-class Product Award is honorable recogni-tion given to top-tier Korean companies including Samsung, Hyundai, and LG.

For ‘EstroG-100’ by Ministry of Knowledge & Economy

65

66

Awards (4)

In recognition of the company’s inte-grated contribution to the growth of the industry through edge-state technology development in agro-fishery food sec-tor.

Presidential Citation (2011)

67

Awards (5)IR52 Chang Young-Sil Award(2009)This Award is normally and in most cases for conglomerates such as Samsung, Hyundai, LG, and for the suppliers for the big companies from Ministry of Education, Science and Technology (2009).

68

Korea Health Industry Award by KFDA 2009

Health Technology Award 2008

Awards (6)

69

Product Merit Award-NBJ (2006)Awarded to the Promising Brand-new Functional Food of the Year

Awards (7)

70

Gold Medal Prize in the Exhibition of Inventions of Geneva (2008)The International Exhibition of Inventions of Geneva is one of the three largest invention expo in the world.

Awards (8)

ESTROG-100I. MISCELLANEOUS

72

Product type-Examples (1)

Baeksuo Gung Baeksuo Secret

Outer Packing 1 paper box 1 paper box

Inner 4 inner boxes 2 inner bottles

Contents6 soft gels/Blister5PTPs/inner box

Total 500mg x 120 capsules(1 month)

56 tablets/bottle

Total 500mg x 112 tablets(2 months)

Dosage 4 capsules per day 2 tablets per day

Formulation Types Soft gels Coated tablet

MOQ

73


8 Symptom Advanced Menopause Relief (CVS)Multi Symptom Menopause Relief (Walgreens) Hwang Hoo Baeksuo


Inner - 2 inner boxes

Contents20 capsules/box

Total 514mg x 28 capsules(1 month)

30 spout pack bags/inner boxTotal 80g x 60 packs

(1 month)

Dosage 1 capsule per day 2 packs per day

Formulation Types Hard capsule Beverage

MOQ

74


Baeksuo Hyoso Baeksuo Queen


Inner 2 paper boxes 2 paper boxes

Contents30 packs/box

Total 3g x 60packs(1 month)

14 packs/boxTotal 22g x 28packs

(1 month)

Dosage 2 packs per day 1 pack per day

Formulation Types Sachet powder Jelly type

MOQ

75


EstroG-100 EstroG-100

Outer Packing 1 bottle 1 bottle

Inner - -

Contents 615mg x 60 capsules(1 month)

700mg x 60 tablets(1 month)

Dosage 2 capsules per day 2 tablets per day

Formulation Types Hard capsule Tablet

MOQ

Naturalendo Tech Co., Ltd.3rd Floor, Bldg A. C’s Tower, 58, 255 St., Pankyo-roBundang-gu, Seongnam-shi, Gyeonggi-do, Korea

www.naturalendo.com

Naturalendo Tech Co., Ltd. Novel Proprietary Standardized Healthcare Ingredient.

Documents

Transcript of Naturalendo Tech Co., Ltd. Novel Proprietary Standardized Healthcare Ingredient.